Citi Reiterates Buy Rating on Immunovant (IMVT)

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/24/2026

1. DECK
2. RNG
3. WDC
4. BYD
5. WCN
6. SPOT
7. BMY
8. SPY
9. FIX
10. TSCO

Go back to Citi Reiterates Buy Rating on Immunovant (IMVT)

Immunovant (IMVT) PT Lowered to $33 at BofA Securities

March 19, 2025 2:59 PM EDT

BofA Securities analyst Jason Gerberry lowered the price target on Immunovant (NASDAQ: IMVT) to $33.00 (from $38.00) while maintaining a Buy rating.... More

Roivant Sciences (ROIV) Announces Positive Results for Batoclimab Myasthenia Gravis and Chronic Inflammatory Demyelinating Polyneuropathy Studies

March 19, 2025 7:45 AM EDT

Immunovant, Inc. (Nasdaq: IMVT), a clinical-stage immunology company dedicated to enabling normal lives for people with autoimmune diseases, today reported topline results from its Phase 3 study of batoclimab in MG and initial results from Period 1 of its Phase 2b study in CIDP.

We are excited to share positive results from our MG and CIDP studies. While neurologists and patients are very enthusiastic about currently approved FcRn inhibitors, they tell us that they also see a lot of potential for a next-generation FcRn inhibitor that can offer deeper and more... More